Brief: Concord Biotech Updates On USFDA Inspection At API Facility At Dholka
24/06/2025 09:35
June 24 (Reuters) - Concord Biotech Ltd CONB.NS: UPDATE ON USFDA INSPECTION AT COMPANY''S API FACILITY AT DHOLKA USFDA ISSUES EIR FOR CONCORD BIOTECH'S DHOLKA FACILITY CLOSURE INDICATES THAT NO REGULATORY ACTION IS REQUIRED Source text: ID:nBSE8M8cxP Further company coverage: CONB.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Concord Biotech
See all newsIndia's Concord Biotech rises after board to consider bonus share issue
Brief: Concord Biotech Ltd June-Quarter Consol Net Profit 585.3 Million Rupees
Brief: Concord Biotech Completes PPB (Kenya) And NDA (Uganda) Inspection At Unit-Ii Formulation Facility
Brief: Concord Biotech Completes Anvisa Inspection At Limbasi API Manufacturing Facility
India's Concord Biotech jumps to 4-month high after US FDA drug approval